盐酸齐拉西酮片与氟哌啶醇片治疗精神分裂症的随机双盲对照研究  

A Double-blind Control Study on Treatment of Schizophrenia with Zipraside Tablet and Haloperidol Tablet

作　　者：卢殿军[1] 宁洁[1] 钟晓妮[2] 

机构地区：[1]重庆市精神卫生中心,重庆401147 [2]重庆医科大学卫生统计学教研室,重庆400046

出　　处：《中国药业》2006年第6期43-44,共2页China Pharmaceuticals

摘　　要：目的评价盐酸齐拉西酮与氟哌啶醇治疗精神分裂症的临床疗效及安全性。方法选择住院患者60例,采用随机双盲法将患者分配至治疗组(30例,口服盐酸齐拉西酮片)与对照组(30例,口服氟哌啶醇片),疗程6周,临床疗效用精神分裂症阳性与阴性症状评定量表(PANSS)评定,安全性用不良反应量表(TESS)评定。结果治疗结束时PANSS减分率治疗组为(60.98±24.04)%,对照组为(62.05±28.31)%,临床总有效率治疗组为80.00%,对照组为73.33%,组间疗效差异无显著性(P>0.05);不良反应发生率治疗组较对照组略少,但组间差异无显著性(P>0.05)。结论盐酸齐拉西酮片治疗精神分裂症的疗效与氟哌啶醇片相当,是一种有效、安全的抗精神病药物。Objective To evaluate the clinical effect and safety of zipraside and halopefidol in the treatment of schizophrenia. Methods 60 inpatients were randomly divided into the subject group （zipraside 30 eases） and control group （haloperidol 30 eases） for 6 weeks. The positive and negative symptom scale （PANSS） was used to assess the indexes of the main effieieneies and the treatment emergent symptom scale （TESS） was used to evaluate the indexes of the safety, Results There were no significant differences of the curative effect （P〉0. 05）. The reduced rates of PANSS were （60.98±24. 04）% in the subject group and （62. 05±28. 31）% in the control group respectively. The total effieieneies were respectively 80. 00% in the subject group and 73.33% in the control group after the end of the treatment with zipraside and halopefidol, Although there was not difference in the side effects between two groups （P 〉 0. 05）, the rate of the side effects was a slight less in the subject group than that in the control group. Conclusion Zipraside is an effective and safe antipsyehotie drug because it is similar in curative effect to halopefidol.

关 键 词：盐酸齐拉西酮片 氟哌啶醇片 精神分裂症 

分 类 号：R969.4[医药卫生—药理学] R971.41[医药卫生—药学]